Check out our comprehensive educational activities here

An expert update on the role of CAR T therapy in AML

Dr. Park briefly explores the challenges and potential of CAR T cell therapy in AML.

Published on November 14, 2018 in Treatment

How do cytogenetics and molecular risk guide your treatment decisions?

Dr. Desai discusses the heterogeneity of AML and why it's so important to have a clear understanding of a patient's genetic profile and risks.

Published on November 5, 2018 in Treatment

Third-generation FLT3 inhibitors in clinical development

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

Published on October 18, 2018 in Treatment

Clinical Challenges with New and Emerging IDH1/IDH2 Inhibitors

Dr. Cortes discusses what to look for when managing patients being treated with an IDH1 or IDH2 inhibitor.

Published on September 24, 2018 in Treatment

Key considerations when prescribing midostaurin with a strong CYP3A4 inhibitor

Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.

Published on September 20, 2018 in Treatment

CAR T case study in acute myeloid leukemia

Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.

Published on July 3, 2018 in Treatment

How are the drugs approved for AML in 2017 changing the therapeutic landscape?

Dr. Daver summarizes the four drug approvals for AML in 2017 and how you should be using these treatments in various patient populations.

Published on June 13, 2018 in Treatment

What is the role of emerging targeted therapies in AML?

Dr. Daver reviews targeted therapies under investigation, recently approved, and near approval in the treatment of AML.

Published on June 6, 2018 in Treatment

What has been found to be the median time to best response with enasidenib?

Dr. Carraway discusses the difference between the median time to response and the median time to best response with enasidenib, and how to properly monitor patients on this drug.

Published on May 23, 2018 in Treatment

What is standard of care for patients unfit for intensive induction chemotherapy, and what is under investigation?

Dr. Daver discusses the best options, both in current standard of care as well as under investigation, for treating patients unfit for intensive chemotherapy (generally patients above the age of 65).

Published on May 9, 2018 in Treatment